Authors’ Reply to Angelis and Kanavos: “Does MCDA Trump CEA?”
They fail completely to address the inadequate treatment of opportunity cost in MCDA and, in particular, its failure to treat cost (whether accounting cost or opportunity cost) in the multidimensional way that is the key characteristic of MCDA. This means that MCDA not only does not attempt to measure the best alternative use of resources but also fails to be consistent with its own principles in its lack of multidimensionality in cost.
They misunderstand our reference to double counting, particularly the MCDA treatment of cost as a criterion additional to cost-effectiveness. Given the size of the cost element in most empirical analyses, this is a tremendous case of double counting. Distinguishing between types of cost and even different concepts of cost is of great importance in cot-effectiveness analysis (CEA) .
Similarly, they sidestep our criticism of ‘independence of criteria’ by introducing an irrelevant confusion with ‘statistical independence’ and ‘preference-independence’ to which we did not refer. Our objection was to the blurred definition of many of the criteria and variables, which greatly magnifies the risk of overlap and overcounting. There is a risk of bias in all methods, but a method that is as imprecise and jumbled as MCDA introduces biases that are virtually impossible to allow for, even when well-designed deliberative decision-making procedures are employed.
Compliance with Ethical Standards
Conflicts of interest
Carlos Campillo-Artero, Jaume Puig-Junoy and Anthony J. Culyer have no conflicts of interest and have not received any funding for this letter.
- 4.Chalkidou K, Li R, Culyer AJ, Glassman A, Hofman KJ, Teerawattananon Y. Health technology assessment: global advocacy and local realities; comment on “priority setting for universal health coverage: we need evidence-informed deliberative processes, not just more evidence on cost-effectiveness. Intl J Health Pol Manag. 2017;6(4):233–6.CrossRefGoogle Scholar
- 6.Culyer AJ, Chalkidou K, Teerawattananon Y, Santatiwongchai B. Rival perspectives in health technology assessment and other economic evaluations for investing in global and national health. Who decides? Who pays? F1000Research. 2018;7:72. https://doi.org/10.12688/f1000research.13284.1.CrossRefGoogle Scholar